Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model

Abstract Background: Medicines for the treatment of 2019-novel coronavirus (2019-nCoV) infections are urgently needed. However, drug screening using live 2019-nCoV requires high-level biosafety facilities, which imposes an obstacle for those institutions without such facilities or 2019-nCoV. This study aims to repurpose the clinically approved drugs for the treatment of coronavirus disease 2019 (COVID-19) in a 2019-nCoV-related coronavirus model. Methods: A 2019-nCoV-related pangolin coronavirus GX_P2V/pangolin/2017/Guangxi was described. Whether GX_P2V uses angiotensin-converting enzyme 2 (ACE2) as the cell receptor was investigated by using small interfering RNA (siRNA)-mediated silencing of ACE2. The pangolin coronavirus model was used to identify drug candidates for treating 2019-nCoV infection. Two libraries of 2406 clinically approved drugs were screened for their ability to inhibit cytopathic effects on Vero E6 cells by GX_P2V infection. The anti-viral activities and anti-viral mechanisms of potential drugs were further investigated. Viral yields of RNAs and infectious particles were quantified by quantitative real-time polymerase chain reaction (qRT-PCR) and plaque assay, respectively. Results: The spike protein of coronavirus GX_P2V shares 92.2% amino acid identity with that of 2019-nCoV isolate Wuhan-hu-1, and uses ACE2 as the receptor for infection just like 2019-nCoV. Three drugs, including cepharanthine (CEP), selamectin, and mefloquine hydrochloride, exhibited complete inhibition of cytopathic effects in cell culture at 10 μmol/L. CEP demonstrated the most potent inhibition of GX_P2V infection, with a concentration for 50% of maximal effect [EC50] of 0.98 μmol/L. The viral RNA yield in cells treated with 10 μmol/L CEP was 15,393-fold lower than in cells without CEP treatment ([6.48 ± 0.02] × 10−4vs. 1.00 ± 0.12, t = 150.38, P < 0.001) at 72 h post-infection (p.i.). Plaque assays found no production of live viruses in media containing 10 μmol/L CEP at 48 h p.i. Furthermore, we found CEP had potent anti-viral activities against both viral entry (0.46 ± 0.12, vs.1.00 ± 0.37, t = 2.42, P < 0.05) and viral replication ([6.18 ± 0.95] × 10−4vs. 1.00 ± 0.43, t = 3.98, P < 0.05). Conclusions: Our pangolin coronavirus GX_P2V is a workable model for 2019-nCoV research. CEP, selamectin, and mefloquine hydrochloride are potential drugs for treating 2019-nCoV infection. Our results strongly suggest that CEP is a wide-spectrum inhibitor of pan-betacoronavirus, and further study of CEP for treatment of 2019-nCoV infection is warranted.

[1]  Ziding Zhang,et al.  Isolation and Characterization of 2019-nCoV-like Coronavirus from Malayan Pangolins , 2020, bioRxiv.

[2]  Jinping Chen,et al.  Viral Metagenomics Revealed Sendai Virus and Coronavirus Infection of Malayan Pangolins (Manis javanica) , 2019, Viruses.

[3]  Jia-Fu Jiang,et al.  Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins , 2020, Nature.

[4]  Huachen Zhu,et al.  Identification of 2019-nCoV related coronaviruses in Malayan pangolins in southern China , 2020, bioRxiv.

[5]  X. Wan,et al.  Are pangolins the intermediate host of the 2019 novel coronavirus (2019-nCoV) ? , 2020, bioRxiv.

[6]  Christian Drosten,et al.  Severe acute respiratory syndrome-related coronavirus: The species and its viruses – a statement of the Coronavirus Study Group , 2020, bioRxiv.

[7]  Sheng Xiong,et al.  Antiviral activity of cepharanthine against severe acute respiratory syndrome coronavirus in vitro. , 2005, Chinese medical journal.

[8]  H. Matsunaga,et al.  Interaction of cepharanthine with immobilized heat shock protein 90α (Hsp90α) and screening of Hsp90α inhibitors. , 2013, Analytical biochemistry.

[9]  Zhe-Sheng Chen,et al.  Recent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs , 2014, Chinese journal of cancer.

[10]  J. Epstein,et al.  Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor , 2013, Nature.

[11]  M. Jang,et al.  Natural Bis-Benzylisoquinoline Alkaloids-Tetrandrine, Fangchinoline, and Cepharanthine, Inhibit Human Coronavirus OC43 Infection of MRC-5 Human Lung Cells , 2019, Biomolecules.

[12]  R. Kariya,et al.  Cepharanthine inhibited HIV-1 cell-cell transmission and cell-free infection via modification of cell membrane fluidity. , 2014, Bioorganic & medicinal chemistry letters.

[13]  M. Rogosnitzky,et al.  Therapeutic potential of the biscoclaurine alkaloid, cepharanthine, for a range of clinical conditions , 2011 .

[14]  Wu Zhong,et al.  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.

[15]  Julie Dyall,et al.  Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection , 2014, Antimicrobial Agents and Chemotherapy.

[16]  E. Holmes,et al.  A new coronavirus associated with human respiratory disease in China , 2020, Nature.

[17]  X. Wan,et al.  Are pangolins the intermediate host of the 2019 novel coronavirus (SARS-CoV-2)? , 2020, PLoS pathogens.

[18]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[19]  Wensheng Wei,et al.  Attachment and Postattachment Receptors Important for Hepatitis C Virus Infection and Cell-to-Cell Transmission , 2017, Journal of Virology.